Alejandro (Alex) Kopelowicz, M.D.

Alejandro (Alex) Kopelowicz, M.D.
Alejandro (Alex) Kopelowicz, M.D.
Affiliated Senior Research Scientist

M.D., Rutgers Medical School
akopelowicz@dhs.lacounty.gov
Phone: (818) 364-4823
Research Interests

Alejandro (Alex) Kopelowicz, M.D. is Professor and Vice-Chair in the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Medical Director of the San Fernando Mental Health Center (SFMHC), a community mental health center operated by the Department of Mental Health of Los Angeles County and Chief of Psychiatry at Olive View-UCLA Medical Center. Dr. Kopelowicz has been a frequent lecturer on biobehavioral treatment and psychiatric rehabilitation techniques. He has written over 100 articles and book chapters on these subjects.

Dr. Kopelowicz has been the recipient of several grants from the National Institute of Mental Health and the National Alliance for Research on Schizophrenia and Depression. His work has focused on culturally adapting evidence-based psychosocial treatment approaches for Hispanic-Americans with serious mental disorders to improve illness self-management, treatment adherence and employment outcomes.

Dr. Kopelowicz was born in Buenos Aires, Argentina and immigrated with his family to New York City at a young age. He remains fluent in Spanish, which has been enormously helpful in his work. He graduated from Haverford College with a B.A. in Psychology, and went on to receive his medical education at Rutgers Medical School in New Jersey. He completed his psychiatric residency at the UCLA/San Fernando Valley program. He is married and he and his wife have three children.

Selected Publications
Kopelowicz A, Baker RA, Zhao C, Sanchez R, Nyilas M, Brewer C, Lawson E, Peters-Strickland T (2017). A Multicenter, Open-label Pilot Study Evaluating the Functionality of an Integrated Call Center for a Digital Medicine System to Optimize Monitoring of Adherence to Oral Aripiprazole in Adult Patients with Serious Mental Illness. Neuropsychiatric Disease and Treatment. 13: 2641-2651.
Buckley PF, Schooler NR, Goff DC, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz AJ, Miller DD, Wilson DR, Ames D, Bustillo J, Kane JM, Looney SW (2016). Comparison of injectable and oral antipsychotics in relapse rates in a pragmatic, 30-month schizophrenia relapse prevention study. Psychiatric Services. 67(12): 1370-72.
Kopelowicz A (2016). Family Psychoeducation In: Schizophrenia and Psychotic Spectrum Disorders, Schulz SC, Green MF, Nelson KT. (Eds.). Oxford University Press: New York. pp. 283-304.
Buckley PF, Schooler NR, Goff DC, Hsiao J, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz A, Miller DD, Severe JB, Wilson DR, Ames D, Bustillo J, Mintz J, Kane JM (2015). Comparison of SGA Oral Medications and a Long-Acting Injectable SGA: The PROACTIVE Study. Schizophrenia Bulletin. 41(2): 449-59.
Kopelowicz A, Zarate R, Wallace CJ, Liberman RP, Lopez SR, Mintz J (2015). Using the Theory of Planned Behavior to improve treatment adherence in Mexican Americans with schizophrenia. Journal of Consulting and Clinical Psychology. 83(5): 985-93.
Kopelowicz A, Zarate R, Wallace CJ, Liberman RP, Lopez SR, Mintz J (2012). The impact of multifamily groups to improve treatment adherence in Mexican Americans with schizophrenia. Archives of General Psychiatry. 69(3): 265-273.
Breitborde N, Lopez SR, Kopelowicz A (2010). Expressed emotion and health outcomes for Mexican Americans with schizophrenia and their caregiving relatives. Journal of Nervous and Mental Disease. 198(2):105-9.
Kopelowicz A, Liberman RP, Wallace CJ, Aguirre F, Mintz J (2009). The effects of olanzapine and risperidone on learning and retaining entry level work skills. Clinical Schizophrenia and Related Psychoses. 3:133-141.